PROSTATE CANCER UK demonstrates an excellent payment speed, with an average payment time of 17 days and 91% of invoices settled within 30 days. This indicates a consistent and highly favourable payment trajectory for suppliers, rarely extending beyond a standard payment cycle.
Payment reliability is high, as 0% of payments extend beyond 60 days, suggesting strong predictability for crucial payments. While 9% of invoices fall into the 31-60 day category, indicating minor sporadic delays, this represents a low-level risk factor with no extremely late payments.
Suppliers can assess PROSTATE CANCER UK as a highly reliable payer with minimal payment risk, given their rapid average payment time and high on-time payment rate. Key decision factors include the 91% within 30 days and zero payments over 60 days; standard credit terms are appropriate, with no significant risk mitigation strategies required beyond typical invoice follow-up for the small percentage of minor delays.
This information is as reported by the business, and responses are in their own words.
Standard payment terms
30 days from date of invoice. These may be varied on a case by case basis.
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
No additional information
Maximum contractual payment period agreed
30
We refer to the contract between the parties as a starting point and will engage in a discussion to find a pragmatic way forward.
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
PROSTATE CANCER UK is an active Private Limited Company by guarantee, specifically structured without share capital and utilising the 'Limited' exemption. Companies of this type are typically established for non-profit purposes, often operating as charities, membership bodies, or research organisations focused on a particular cause.
The company holds company number 02653887 and was incorporated on 14 October 1991. Its registered office is located in London, at The Counting House Fourth Floor, 53 Tooley Street, SE1 2QN.
Organisations structured as a Private Limited Company by guarantee, particularly those focused on health conditions, typically engage in a range of activities. These commonly include funding and facilitating research, conducting public awareness campaigns, providing support services for those affected, and advocating for policy changes to improve care. Such organisations also frequently undertake fundraising initiatives to support their objectives.